ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Average Price Target of $25.00

Key Points

• Analysts have a Moderate Buy consensus on ARS Pharmaceuticals, with four buy ratings, one hold, and one sell; the average 12-month price target is $25.00.
• SPRY opened at $4.03, near its 52-week low of $3.81, while its 50-day and 200-day moving averages stood at $4.81 and $6.82, respectively.
• ARS Pharmaceuticals missed quarterly EPS estimates, reporting a loss of $0.63 per share versus the expected $0.48 loss, though revenue of $33.66 million exceeded estimates. Institutional investors and hedge funds own 68.16% of the company.

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $25.00.

Several research analysts recently weighed in on the company. Weiss Ratings cut ARS Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Monday, August 17th. Leerink Partners set a $15.00 price target on shares of ARS Pharmaceuticals in a research report on Tuesday, September 8th.

ARS Pharmaceuticals Stock Performance

SPRY opened at $4.03 on Monday. The company has a market capitalization of $400.78 million, a price-to-earnings ratio of -1.85 and a beta of 0.85. The company has a debt-to-equity ratio of 13.72, a current ratio of 3.48 and a quick ratio of 3.28. ARS Pharmaceuticals has a 1-year low of $3.81 and a 1-year high of $13.15. The business has a 50 day moving average price of $4.81 and a two-hundred day moving average price of $6.82.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.15). The firm had revenue of $33.66 million for the quarter, compared to analyst estimates of $31.32 million. ARS Pharmaceuticals had a negative net margin of 184.24% and a negative return on equity of 256.67%. Research analysts predict that ARS Pharmaceuticals will post -1.91 EPS for the current fiscal year.

Hedge Funds Weigh In On ARS Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. USAdvisors Wealth Management LLC acquired a new position in ARS Pharmaceuticals in the third quarter worth approximately $43,000. WINTON GROUP Ltd acquired a new stake in shares of ARS Pharmaceuticals during the 2nd quarter valued at $264,000. Engineers Gate Manager LP lifted its position in shares of ARS Pharmaceuticals by 195.0% during the 2nd quarter. Engineers Gate Manager LP now owns 139,419 shares of the company's stock valued at $1,117,000 after acquiring an additional 92,163 shares during the last quarter. Allianz Asset Management GmbH acquired a new stake in shares of ARS Pharmaceuticals during the 2nd quarter valued at $82,000. Finally, Corient Private Wealth LP lifted its position in shares of ARS Pharmaceuticals by 12.5% during the 2nd quarter. Corient Private Wealth LP now owns 91,042 shares of the company's stock valued at $729,000 after acquiring an additional 10,099 shares during the last quarter. Institutional investors and hedge funds own 68.16% of the company's stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc NASDAQ: SPRY is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company's lead product is neffy (epinephrine nasal spray), a needle-free alternative to injectable epinephrine designed for the emergency treatment of allergic reactions, including anaphylaxis.

Neffy was approved by the U.S. Food and Drug Administration in 2024 for adults and pediatric patients who weigh at least 30 kilograms. The product is intended to provide rapid, convenient administration without requiring a syringe or injector, which may help address barriers associated with the use of traditional epinephrine auto-injectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.